Merrimack Pharmaceuticals... (MACK)
NASDAQ: MACK
· Real-Time Price · USD
15.14
0.01 (0.07%)
At close: May 17, 2024, 9:59 PM
Merrimack Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | -445K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | 445K | n/a | n/a | n/a | 144K | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | -890K | n/a | n/a | n/a | -144K | n/a | n/a | n/a |
Operating Income | -669K | -490K | -531K | -569K | -447K | -607K | -504K | -486K | -132K | -473K | -525K | -778K | -696K |
Interest Income | 233K | 262K | 252K | 178K | 176K | 118K | 62K | 8K | n/a | 1K | n/a | 19K | n/a |
Pretax Income | -436K | -228K | -279K | -391K | -271K | -489K | -442K | -478K | -132K | -472K | -525K | -759K | -696K |
Net Income | -23.63M | -240K | -279K | -391K | -95K | -492K | -318K | -462K | -132K | -475K | -525K | -759K | -696K |
Selling & General & Admin | 669K | 490K | 531K | 569K | 586K | 607K | 504K | 486K | 577K | 473K | 619K | 778K | 746K |
Research & Development | n/a | 139K | n/a | n/a | 139K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | 139K | n/a | n/a | -139K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 669K | 490K | 531K | 569K | 586K | 607K | 504K | 486K | 577K | 473K | 619K | 778K | 746K |
Interest Expense | n/a | 176K | n/a | n/a | n/a | n/a | 62K | 8K | n/a | 1K | n/a | 19K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 669K | 490K | 531K | 569K | 586K | 607K | 504K | 486K | 577K | 473K | 619K | 778K | 746K |
Income Tax Expense | 23.19M | 12K | -531 | -569 | -176K | 3K | -124K | -16K | n/a | 1K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 14.45M | 14.34M | 14.32M | 14.29M | 14.25M | 13.77M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.4M |
Shares Outstanding (Diluted) | 14.45M | 14.34M | 14.32M | 14.29M | 14.25M | 13.77M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.41M | 13.4M |
EPS (Basic) | -1.64 | -0.02 | -0.02 | -0.03 | -0.01 | -0.04 | -0.02 | -0.03 | -0.01 | -0.04 | -0.04 | -0.06 | -0.05 |
EPS (Diluted) | -1.64 | -0.02 | -0.02 | -0.03 | -0.01 | -0.04 | -0.02 | -0.03 | -0.01 | -0.04 | -0.04 | -0.06 | -0.05 |
EBITDA | -669K | -490K | -531K | -569K | -725K | -607K | -504K | -486K | -1.02M | -473K | -713K | -778K | -796K |
EBIT | n/a | -52K | n/a | n/a | -447K | n/a | -380K | -470K | -132K | -471K | -525K | -740K | -696K |
Depreciation & Amortization | 43.28K | 43.81K | -39.59K | 122.08K | -278K | -140K | 27.08K | 86.06K | -890K | -1K | -188K | 55.81K | -100K |